Feb 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Albemarle, Moderna and Newmont, on Monday.
HIGHLIGHTS
* Albemarle ALB.N: RBC raises target price to $216 from $200
* Moderna MRNA.O: RBC raises target price to $30 from $25
* Newmont NEM.N: Jefferies raises target price to $158 from $136
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.
* Albemarle ALB.N: RBC raises target price to $216 from $200
* Cognex Corp CGNX.O: Daiwa Capital Markets raises target price to $65 from $45
* Dupont DD.N: RBC raises target price to $60 from $51
* Eagle Materials Inc EXP.N: JP Morgan cuts target price to $215 from $230
* Eagle Materials Inc EXP.N: JP Morgan cuts to underweight from neutral
* Expedia Group Inc EXPE.O: Jefferies cuts target price to $240 from $285
* Maplebear Inc CART.O: Jefferies cuts target price to $38 from $44
* Moderna MRNA.O: Jefferies raises target price to $37 from $30
* Moderna MRNA.O: RBC raises target price to $30 from $25
* Newmont NEM.N: Jefferies raises target price to $158 from $136
* Royal Gold Inc RGLD.O: Jefferies raises target price to $390 from $320
* Toast Inc TOST.N: Bernstein raises to outperform from market-perform
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
